

---

# Health NCP Net

InfoDay Cluster 1 “Health”  
Q&A on Calls 2026

---

[www.healthncp.net](http://www.healthncp.net)



HNN3.0 (The Cluster 1 Health consortium of NCPs for Horizon Europe) has received funding from the European Union's Horizon EUROPE research and innovation programme under Grant Agreement number 101057279

## INTRODUCTION AND BACKGROUND

On February 10<sup>th</sup>, 2026, a virtual [Horizon Europe Info Day](#) was organized for the health cluster by the European Commission. This Info Day aimed to inform (potential) applicants about topics included in the Cluster 1 'Health' Work Programme of 2026.

The European Commission has published the slides and videos of the topic presentations and the questions and answers (Q&A) online.

This document prepared by NCPs will give you the links to all topic presentations and Q&A sessions including the exact time in the video where the questions are answered.

The aim of this document is to help Health NCPs provide their applicants with the best possible advice and support and to assist applicants in preparing a high-quality application.

This document is provided for information only. It has been written as part of the HNN 3.0 project, a Coordination and Support Action funded by the European Commission, with the goal to improve and support the professionalization of the services rendered by Cluster 1 – Health NCPs across Europe, helping for a simpler access to different health related Horizon Europe calls, lowering the entry barriers for newcomers and raising the average quality of the submitted proposals.

## Contents

Cross-cutting issues.....	3
Destination 1 - Staying healthy in a rapidly changing society .....	4
Destination 2. Living and working in a health-promoting environment.....	5
Destination 3. Tackling diseases and reducing disease burden.....	7
Destination 4. Ensuring access to innovative, sustainable and high-quality health care .....	10
Destination 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society .....	11
Destination 6. Maintaining an innovative, sustainable and globally competitive health industry.....	12

## Cross-cutting issues

Read our HNN 3.0 [Annotated template on clinical studies](#) and watch the linked presentations on [Clinical Studies](#), [Social Science and Humanities integration](#), [financial matters](#) and [HNN 3.0 - NCP services](#).

Watch the whole [Q&A on Cross cutting issues](#), part of the Horizon Europe info day: Cluster 1 (morning sessions) video.

General Questions	Link to answer
1. When should clinical studies be used? It seems not relevant for many proposals.	<a href="#">36:10</a>
2. What about topics with no-obligatory trials and single stage proposals?	<a href="#">46:03</a>
3. Where it is possible to find the conditions for each Topic Call?	<a href="#">39:10</a>
4. SSH integration is considered important in SSH flagged topics. We would like to include SSH participants in a non SSH-flagged topic. Could this be equally important?	<a href="#">40:40</a>
5. Could you please share more information on the China restrictions in Cluster 1?	<a href="#">41:17</a>
6. Are Chinese universities allowed to participate in work programme 26-27 topics?	<a href="#">59:09</a>
7. Can you give financial specificities for involving some countries outside Horizon beneficiary countries in the consortia (though that may depend on the country and also on the specific call)?	<a href="#">43:34</a>
8. Can you confirm that Japanese/USA entities can participate as beneficiaries starting from the 2026 calls?	<a href="#">45:01</a>
9. For Korean participation in HE is the minimum consortium of three independent legal entities from three different EU or associated countries with at least one from an EU member state still applicable?	<a href="#">1:00:03</a>
10. Can you please confirm whether proposals are evaluated exclusively on their content without consideration of whether AI tools were used to during the preparation? (Whether there is any obligation to declare the use of AI tools in the proposal)	<a href="#">48:25</a>
11. What is the minimum number of countries required in the proposing consortium?	<a href="#">49:25</a>
12. Do you have an update on the in the lump-sum funding excel spreadsheet?	<a href="#">51:34</a>
13. How many people should be on each team in each participating country? Can research staff, doctor students or doctors participate whether or not they are affiliated with the university?	<a href="#">53:36</a>
14. Can you clarify the hierarchy of eligibility conditions in general annex?	<a href="#">55:00</a>
15. In lump-sum projects are organizations receiving an operating grant eligible for indirect costs?	<a href="#">56:12</a>
16. Is there a budget template that should be used for stage-one submissions in two-stage topics?	<a href="#">57:13</a>
17. What resources do you recommend for finding complimentary EU partners?	<a href="#">1:01:16</a>
18. In case a beneficiary wants to transfer ownership or grant an exclusive license, what should they do?	<a href="#">1:04:13</a>
19. When can the granting authority object to a transfer or licensing?	<a href="#">1:09:14</a>

20. Please advise on whether a non-EU organization can lead a consortium for environmental health for our activities restricted to EU region or can they be undertaken by low- and middle-income countries?	<a href="#">1:06:09</a>
21. How is it possible to find who is the national contact point in different countries?	<a href="#">1:07:42</a>
22. We heard in Switzerland that if the vote on limiting number of inhabitants to 10 million will be accepted in June, Switzerland might be excluded from Horizon Europe as a beneficiary. Is that correct or not? What would happen to submitted projects?	<a href="#">1:10:20</a>
23. For organizations interested in coordinating a project: how relevant is previous experience as a coordinator? Are there realistic chances without it? Could you provide recommendation how best to approach this?	<a href="#">1:11:57</a>
24. Some topics include "international cooperation is encouraged". What exactly does international mean, non-EU countries?	<a href="#">1:15:41</a>
25. What are the capacities a coordinating team should have in place to be able to shoulder this burden, the burden of coordination? What are the challenges beyond what the work package leaders have?	<a href="#">1:18:17</a>
26. What types of general recommendations do you have for composing a convincing and successful consortium in research and innovation actions under cluster one?	<a href="#">1:25:29</a>
27. Can ministries be a partner of the project? If yes, then at what status?	<a href="#">1:27:34</a>
28. Could an international entity like WHO or similar be part of the consortium?	<a href="#">1:29:00</a>

## **Destination 1 - Staying healthy in a rapidly changing society**

Watch the presentations of [Destination 1 Topics](#) and the [whole Q&A on Destination 1](#), which is part of the Horizon Europe info day: Cluster 1 (morning sessions) video.

**HORIZON-HLTH-2026-01-STAYHLTH-02:** Behavioral interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people

Questions	Link to answer
1. Is it sufficient to focus on behavioral risk factors for major NCD, like tobacco, nicotine, alcohol, stress, inactivity, rather than on a single disease outcome, provided that the link to major NCDs is clearly justified?	<a href="#">1:41:22</a>
2. Does the Commission consider innovation in delivery integration across settings and digital support of existing interventions rather than development of new interventions as sufficient innovation under this call?	<a href="#">1:42:45</a>
3. Would it be acceptable under call STAYHLTH-02 to implement different evidence-based behavioral interventions in different countries, as long as they target the same risk factors and share comparable core mechanisms?	<a href="#">1:43:39</a>
4. From the Commission's perspective, what would be the main weaknesses of an implementation-focused project using existing evidence-based interventions, and what would reviewers most critically look for in such proposals?	<a href="#">1:45:05</a>
5. Are neurodevelopmental disorders considered non communicable diseases?	<a href="#">1:46:13</a>
6. Why is Cancer excluded from this topic?	<a href="#">1:47:23</a>

7. Not real definition by WHO: "NCDs linked to behavioural, metabolic, environmental and socioeconomic risk factors"	<a href="#">1:48:03</a>
8. What is the background/reason for the call being limited to include ages 12–25? Is it possible to choose to include only some of these ages, for example 12–15 years?	<a href="#">1:50:06</a>
9. Would reducing the impact of social media on eating disorders or risk factors for them, as well as mental health indicators, through programmes in secondary schools be a fit topic for this proposal?	<a href="#">1:52:34</a>
10. Some NCDs are related to the abuse of social media, for instance, obesity, metabolic diseases and so on as well as mental diseases, is this included also if there is a specific topic on social media or is this excluded?	<a href="#">1:54:57</a>

### HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences

Question	Link to answer
1. Regarding the repository of tools and support for risk communication: since such tools already exist, what added value are you expecting under this project?	<a href="#">1:56:34</a>

## **Destination 2. Living and working in a health-promoting environment**

Watch the presentation of [Destination 2 Topics](#) and the [whole Q&A on Destination 2](#), which is part of the Horizon Europe info day: Cluster 1 (morning session).

### HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health

Questions	Link to answer
1. Can proposals focus on both mental health and non-communicable diseases?	<a href="#">2:13:10</a>
2. Would the inclusion of animal models be of disadvantage for this topic?	<a href="#">2:13:55</a>
3. Does the development of longitudinal studies in the call refer to the creation of new longitudinal cohorts, or can existing longitudinal cohorts be considered as well?	<a href="#">2:23:24</a>
4. Do proposals wanting to look at vector borne diseases need to include the participation of LMICs?	<a href="#">2:24:13</a>
5. There is a mention of injury and death in the call scope. What is precisely meant by injury?	<a href="#">2:32:18</a>
6. Is it possible to focus on a specific subgroup of infectious diseases, such as foodborne or vector-borne diseases?	<a href="#">2:34:38</a>

### HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems

Questions	Link to answer
1. To which degree does the call allow/encourage international collaborations with African countries, e.g. on evaluating climate-health co-benefits of agroforestry there? Could that be a substantial part of a successful proposal?	<a href="#">2:15:18</a>
2. What is meant by "frameworks" in expected outcomes: "The healthcare sector is supported with new technological developments and frameworks for greening, decarbonising and adapting to climate change..."?	<a href="#">2:16:51</a>
3. The call is very broad. Is it expected that each consortium tries to cover as much ground as possible or is it rather envisioned that each consortium focuses on only some aspects and goes deeper there?	<a href="#">2:17:41</a>
4. "should include some of the following activities"... would proposals need to focus on either adaptation and mitigation, or do proposals need to mix the two?	<a href="#">2:20:19</a>
5. In the call it says proposals should address most of the expected outcomes. Does this mean that funding chances are higher for proposals that address a larger number or all of the outcomes than those focusing on some?	<a href="#">2:21:40</a>
6. The ENVHEALTH-04 call says research activities should generate evidence on health co-benefits as well as develop low-carbon medical technologies and digital solutions. Do consortia need to do both or can they pick one?	<a href="#">2:22:22</a>
7. Should research activities generate evidence on health co-benefits of mitigation only "in the health sector" or in general? What is the definition of "health sector", does it include prevention, e.g. mobility or food?	<a href="#">2:24:50</a>
8. This call appears to address two major issues: 1) how healthcare impacts climate change and 2) how climate change impacts health. Is this a correct interpretation? Is it necessary to address both aspects in the proposal?	<a href="#">2:26:39</a>
9. To which degree does the call encourage international collaboration with (eligible) non-EU countries like the U.S. and low-income countries? Is it an advantage to include partners there?	<a href="#">2:28:33</a>
10. Proposals should support the design of transferable interventions that can then be applied widely. Does this mean one is not expected to evaluate interventions? Or just as case studies? How many would be recommended?	<a href="#">2:30:23</a>
11. Is a technology part necessary and if so, how much emphasis does this part need? What do you understand by technology?	<a href="#">2:35:20</a>

### HORIZON-HLTH-2026-01-ENVHLTH-05: Support for a multilateral initiative on climate change and health research

Questions	Link to answer
1. What type of organisations would you envision leading the CSA?	<a href="#">2:14:12</a>
2. Is the CSA also supposed to provide financial support to the activities of the multilateral initiative?	<a href="#">2:19:31</a>
3. The text of the call mentions that the CSA should build on the preparatory work done. What does this mean?	<a href="#">2:33:10</a>

### **Destination 3. Tackling diseases and reducing disease burden**

Watch the presentation of [Destination 3 Topics](#) and the [whole Q&A on Destination 3](#), which is part of the Horizon Europe info day: Cluster 1 (afternoon sessions)

**HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults**

Questions	Link to answer
1. The topic mentions both digital and innovative intervention creating uncertainty about the scope. Could you clarify whether non-digital or hybrid digital non-digital approaches are eligible?	<a href="#">5:38</a>
2. May proposals focus on specific subgroups of children or young adults, or are interventions expected to cover 0–24 years? Are there any specific age groups that must be included? (edited)	<a href="#">7:07</a>
3. Are retrospective and prospective clinical studies in scope? Are clinical trials (i.e. sponsored studies) in scope?	<a href="#">12:14</a>
4. Are projects expected to focus on understanding the impact of digital technologies or the impact of digital content, on mental health?	<a href="#">17:08</a>
5. Is there a limit on the number of consortium partners? Is there a limit on the number of participating chairs/professorships within one university?	<a href="#">22:03</a>
6. Are there any specific digital technologies that are particularly targeted or should be or are any explicitly excluded?	<a href="#">30:34</a>
7. To what extent does the call focus on the therapeutic approaches?	<a href="#">32:05</a>
8. Participation of startups and SMEs is encouraged. It should be or not ultimately required?	<a href="#">36:17</a>
9. Should early childhood kindergarten age be considered in this topic?	<a href="#">37:36</a>
10. Would leveraging the potential of DT also imply digital technologies?	<a href="#">39:27</a>
11. Can the intervention be developed as part of the call or do they need to be established?	<a href="#">44:29</a>
12. Does the commission expect interventions targeting specific platforms like for example social media gaming or is a broader ecosystem approach preferable?	<a href="#">45:32</a>
13. Can the project built on the complemented studies and the ongoing intervention within the consortium and extend them or do both the studies and the intervention need to be entirely novel?	<a href="#">48:21</a>
14. The scope includes both intervention and neurobiological evidence. Should this be weighted equally or should the neurological component play a more supporting role for the intervention?	<a href="#">49:36</a>
15. Are there any specific ages required for this call? Also is it necessary for the intervention to be digital?	<a href="#">51:11</a>

### HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions

Questions	Link to answer
1. What is the expected TRL level for projects submitted to the call?	<a href="#">10:57</a> (not answered)
2. Are HIV/AIDS and tuberculosis in scope? They seem to be considered chronic infectious diseases (H2020-SC1-2016-2017 FAQ). Could you please confirm?	<a href="#">13:17</a>
3. It is written that the pharmacological intervention they should be phase I or I, but in case of repurposing it should be a different phase. Would this be acceptable?	<a href="#">21:16</a>
4. Does complimentary in this topic mean that the number of the consortium must already be involved in a related proposal, or is the call genuinely open to entirely new applicants and consortia?	<a href="#">25:28</a>
5. Proposals must complement previously funded project while remaining sufficiently innovative. Is it mandatory to form a consortium with partners from related calls or to exchange information with them?	<a href="#">29:04</a>
6. Would a treatment that has already completed or entered phase 2 clinical trial for a different indication be considered eligible under this topic?	<a href="#">43:09</a>

### HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

Questions	Link to answer
7. Does the call expect the full execution of a Phase 1 Clinical trial within the scope, or is the GMP manufacturing of the candidate vaccine considered sufficient as enabling clinical work?	<a href="#">8:20</a>
8. "Novel vaccines" and contrasting "existing vaccines" are mentioned in this call, please clarify novel vs existing vaccines and how this relates to novel/existing vaccine antigens, or novel/existing vaccine platforms.	<a href="#">9:25</a>
9. The proposed work should aim to advance the development of vaccine candidates targeting exclusively one of the following viruses: ..." Does this mean that cross-protective vaccines are out of scope portfolio approach	<a href="#">16:01</a>
10. Flaviviridae: Tick-borne encephalitis virus (TBEV) is not listed anymore in the call text. TBEV is a pandemic disease without vaccine. Any specific reason for moving it out from this call?	<a href="#">19:41</a>
11. The viruses addressed in this call are particularly endemic in Argentina, Asia and America. So are institutions based in these countries' regions eligible for funding under this call?	<a href="#">26:12</a>
12. For this topic is it important to consider a One Health approach as most of these viruses are transmitted by wild animals?	<a href="#">38:40</a>

**HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)**

Questions	Link to answer
1. Is a given country listed in the World Bank as upper middle country considered under the low- and middle-income country group	<a href="#">14:04</a>
2. Out of scope notice includes epidemiological cohorts. Does this apply to retrospective evaluation of patients' data to analyse some risk factors? So, what is the creation of new cohorts?	<a href="#">23:37</a>
3. Call announcement states proposals under this topic are expected to include clinical studies. The use of the template is strongly encouraged. Is it the hard requirement to include clinical study under this call or not.	<a href="#">24:40</a>
4. Does this topic allow to target preventive interventions?	<a href="#">34:21</a>
5. Can United States continue to be partner in the consortium?	<a href="#">35:05</a>
6. May a partner from a low- and middle-income country out of Horizon 20 associated countries take part in the implementation research?	<a href="#">42:21</a>
7. If all partners of the project are from high income countries and implemented in high income countries but specifically targets only the elderly, would it be considered eligible in terms of the consortium structure?	<a href="#">46:37</a>

**HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways**

Questions	Link to answer
1. We are considering including an animal model to investigate the underlying mechanistic pathways. Could this raise ethical concerns that might affect the evaluation of the project?	<a href="#">11:37</a>
2. For the SSH requirement, would the involvement of researchers working on occupational psychosocial determinants of disease be considered sufficient SSH integration for this call?	<a href="#">14:47</a>
3. Is looking at pregnancy enough to justify the sex-related view? Or is it necessary to do the comparison between sexes/genders?	<a href="#">18:56</a>
4. As the title reads understanding of sex and or gender specific mechanism of cardiovascular diseases will the proposal be penalized if they only consider sex or gender?	<a href="#">27:15</a>
5. Have proposals focusing on rare diseases less chances even if the applied approach may represent a template for future investigation of more common diseases?	<a href="#">40:33</a>
6. Are rather widespread diseases like atherosclerosis in the focus of the call?	<a href="#">42:08</a>

## Destination 4. Ensuring access to innovative, sustainable and high-quality health care

Watch the presentation of [Destination 4 Topics](#) and the [whole Q&A on Destination 4](#), which is part of the Horizon Europe info day: Cluster 1 (afternoon sessions).

**HORIZON-HLTH-2026-01-CARE-01:** Public procurement of innovative (PPI) solutions for improving citizens' access to healthcare through integrated or personalised approaches

Questions	Link to answer
1. Would it be possible to know if part of the EU Funding (50%) could be dedicated to procuring the innovative solution? (PPI for improving citizens' access to healthcare through integrated or personalised approaches)	<a href="#">1:16:40</a>
2. Which stakeholders should answer to this topic? Can they be academic actors or Industry?	<a href="#">1:19:21</a>
3. Is there a possibility to use the EU Funding for the procurement of the solution? and if yes, which percentage of the EU budget could be dedicated to it? (PPI HORIZON-HLTH-2026-01-CARE-01) - Example: as for the PPI RaDAR GA N° 101036228	<a href="#">1:23:35</a>
4. In the past some PCP actions were funded by the EU R&I funding, and several of these actions have just finished (or are about to). Is this PPI topic a follow up topic for these PCPs?	<a href="#">1:28:08</a>
5. What are the main differences in funding conditions for pre-commercial procurement (PCP) vs public procurement of innovative solutions (PPI) calls? - asked on cross-cutting issues session, was requested to submit it to Destination 4 session	<a href="#">1:32:24</a>

**HORIZON-HLTH-2026-01-CARE-03:** Identifying and addressing low-value care in health and care systems

Questions	Link to answer
1. Would cancer focused proposals, or any other specific disease areas, in scope of this topic?	<a href="#">1:17:57</a>
2. Are clinical studies mandatory or are other types of evidence (e.g. pilot studies, modeling) acceptable?	<a href="#">1:20:30</a>
3. Is the focus limited to clinical low-value care practices or does it also include administrative or organizational low-value practices	<a href="#">1:21:06</a>
4. What level of involvement is expected from health authorities, payers, providers or professional bodies?	<a href="#">1:24:34</a>
5. The topic suggests considering "alternative financing models". Can they be theoretical level models without the requirement to be "piloted" in real-life setting?	<a href="#">1:26:22</a>
6. Is it imperative for proposals to implement interventions to reduce slow-value care in the clinical setting? Would a proposal that only uses data to identify LVC activities and develop strategies be admissible?	<a href="#">1:29:35</a>
7. I am writing to request clarification regarding the possibility of establishing synergies with a nationally funded project. It's no overlap of activities and no risk of double funding.	<a href="#">1:31:20</a>

8. What is the difference between health and care systems and healthcare organisations?	<a href="#">1:33:32</a>
9. What do they exact expect with "pilot strategies" if not a clinical study?	<a href="#">1:35:16</a>

## **Destination 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society**

Watch the presentation of [Destination 5 Topics](#) and the [whole Q&A on Destination 5](#), which is part of the Horizon Europe info day: Cluster 1 (afternoon sessions).

<b>General Questions</b>	<b>Link to answer</b>
1. For the 2026 Cluster 1 health calls, will there be specific topics focusing on innovative molecular biomarkers, such as extracellular vesicles, for cancer diagnosis or stratification?	<a href="#">1:48:52</a>

### **HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing**

<b>Questions</b>	<b>Link to answer</b>
1. To validate a NAM for a particular disease. In addition to reference drugs, is it in the scope of the topic to include validation tasks with a new molecule under development?	<a href="#">1:43:06</a>
2. The granting authority may, up to four years after the end of the action object to a transfer. Could you please clarify in which situations this may occur and what implications has at implementation level?	<a href="#">1:45:44</a>
3. Is it necessary to address both use cases for biomedical research and regulatory/safety assessment?	<a href="#">1:46:53</a>
4. Please clarify the role of clinical studies in this topic. How can clinical studies be integrated in this topic, particularly in light of the R&D and regulatory focus of the NAMs. How does this fit?	<a href="#">1:47:12</a>
5. Is JRC-ECVAM's involvement requested to be included in the proposal from the beginning? Or just after, if the proposal funded?	<a href="#">1:48:01</a>
6. If the proposal involves comparing patients' tissues with hiPSC-derived 3D tissue models, should the clinical study template be provided with the proposal?	<a href="#">1:48:18</a>
7. Would our project still align well with the central goal of the topic, if fits expected outcomes 1-3,5 (NAMs to researchers, industry access, patient benefit, build regulatory trust), but has weak-no reduction in animal use (EO 6)?	<a href="#">1:49:26</a>
8. Regarding AI Analysis, is it necessary to build predictive models and/or digital twin systems? Or is it sufficient to build AI models that "only" analyze complex biomedical data and extract significant features from them?	<a href="#">1:51:45</a>
9. How much is important the ethical activities? And in which terms? Do you suggest having a specific WP for the ethical topic?	<a href="#">1:52:34</a>

## HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine

Questions	Link to answer
1. Is it enough to have preclinical validation?	<a href="#">1:44:55</a>
2. Should ALL the activities start at TRL 5?	<a href="#">1:50:26</a>

## **Destination 6. Maintaining an innovative, sustainable and globally competitive health industry**

Watch the presentation of [Destination 6 Topics](#) and the [whole Q&A on Destination 6](#), which is part of the Horizon Europe info day: Cluster 1 (afternoon sessions).

## HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centered health technologies

Questions	Link to answer
1. How far beyond today's regulatory rules are projects expected to go when formulating their recommendations under this topic?	<a href="#">2:27:10</a>
2. Are high quality data platforms for the establishment of AI/synthetic data/virtual patient cohorts for accelerated regulatory approval and access to ATMP development in scope of this call?	<a href="#">2:28:30</a>
2. What type of health technologies are included in the topic? Are pharmaceutical products included?	<a href="#">2:29:34</a>
3. It is written that "clinical studies are out of scope". To do a pilot in a regulatory sandbox, we need existing data for the assessment of the health technology (retrospective, synthetic). Is the clinical annex needed?	<a href="#">2:30:22</a>
4. Would a project establishing a regulatory science platform for biomarker validation, qualification and secure data sharing, enabling faster reliable translation of biomarkers into clinical applications, be eligible?	<a href="#">2:31:13</a>
5. Are international comparisons with LMIC (frugal innovation) and other global countries of interest for this call?	<a href="#">2:32:38</a>
6. Are health technologies related to drugs treatment (digital therapies) in scope, if there are medical devices driven by AI?	<a href="#">2:33:22</a>
7. Would indoor air quality monitoring technologies with AI integration in clinical settings or cultural settings be eligible?	<a href="#">2:34:31</a>
8. For the regulatory sandbox pilot (under development in MS), do you expect that a pilot simulation (with notified bodies, regulators, industries, patient) already taking place during the project?	<a href="#">2:35:50</a>
9. Is the policy goal to contribute to new center patient template-path for digital medical devices?	<a href="#">2:36:46</a>

*The concept and development process of this document belongs to the HNN3.0 network and is based on official information provided by European Commission experts during the HE 2026 Info Days.*